Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Shareholder Pattern
Shareholding breakup across reporting periods.
| Sep 2026 | |
|---|---|
| Promoters + | 68.13% |
| FIIs + | 7.54% |
| Public + | 24.34% |
| No. of Shareholders | 474 |
Financials of Himalaya Nutravedics
Quarter-by-quarter operating performance
| Sales + |
| Expenses + |
| Operating Profit |
| OPM % |
| Other Income + |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| Net Profit + |
| EPS in Rs |
Financials of Himalaya Nutravedics
Annual income statement trend
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales + | 2.05 | 14.43 | 21.00 | 43.06 |
| Expenses + | 1.77 | 13.49 | 18.01 | 34.95 |
| Operating Profit | 0.28 | 0.94 | 2.99 | 8.11 |
| OPM % | 13.66% | 6.51% | 14.24% | 18.83% |
| Other Income + | 0.00 | 0.00 | 0.00 | 0.05 |
| Interest | 0.02 | 0.18 | 0.32 | 0.35 |
| Depreciation | 0.06 | 0.16 | 0.42 | 0.33 |
| Profit before tax | 0.20 | 0.60 | 2.25 | 7.48 |
| Tax % | 25.00% | 28.33% | 0.89% | 1.20% |
| Net Profit + | 0.15 | 0.43 | 2.23 | 7.39 |
| EPS in Rs | 1.81 | 5.18 | 5.58 | 11.72 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
Financials of Himalaya Nutravedics
Capital structure and asset base
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 0.83 | 0.83 | 4.00 | 6.31 |
| Reserves | 0.15 | 0.53 | 2.76 | 10.07 |
| Borrowings + | 1.32 | 3.24 | 1.76 | 5.13 |
| Other Liabilities + | 0.93 | 1.49 | 2.30 | 2.91 |
| Total Liabilities | 3.23 | 6.09 | 10.82 | 24.42 |
| Fixed Assets + | 0.58 | 1.50 | 1.29 | 1.03 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.02 | 0.03 | 0.07 |
| Other Assets + | 2.65 | 4.57 | 9.50 | 23.32 |
| Total Assets | 3.23 | 6.09 | 10.82 | 24.42 |
Financials of Himalaya Nutravedics
Operating, investing and financing cash movement
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Cash from Operating Activity + | -0.55 | -1.39 | -3.83 | |
| Cash from Investing Activity + | -1.10 | -0.23 | -0.06 | |
| Cash from Financing Activity + | 1.84 | 1.44 | 5.27 | |
| Net Cash Flow | 0.19 | -0.18 | 1.38 | |
| Free Cash Flow | -1.63 | -1.60 | -3.90 | |
| CFO/OP | -40% | -46% | -46% |
Financials of Himalaya Nutravedics
Working capital efficiency and return ratios
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 169.15 | 39.21 | 98.03 | 89.77 |
| Inventory Days | 735.53 | 112.03 | 96.55 | 142.67 |
| Days Payable | 60.83 | 27.56 | 37.68 | 11.20 |
| Cash Conversion Cycle | 843.84 | 123.68 | 156.90 | 221.24 |
| Working Capital Days | 295.56 | 6.58 | 97.85 | 104.69 |
| ROCE % | 22.61% | 39.18% | 52.15% |
Operating Margin: Operating Margin = (EBITDA / Revenue from operations) × 100 = (2,770.29 / 14,791.49) × 100 ≈ 18.73% . Key results statement takeaways from Baj
Granules plans to invest about ₹2,000 crore in organic capital expenditure over the next 3-4 years. Key concall takeaways from Granules India Ltd's Q2 FY27…
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium